<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01774968</url>
  </required_header>
  <id_info>
    <org_study_id>14838</org_study_id>
    <secondary_id>B5K-US-IBHC</secondary_id>
    <nct_id>NCT01774968</nct_id>
  </id_info>
  <brief_title>Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes</brief_title>
  <official_title>Two Treatment Approaches for Human Regular U-500 Insulin (Thrice-Daily Versus Twice-Daily) in Subjects With Type 2 Diabetes Mellitus Not Achieving Adequate Glycemic Control on High-Dose U-100 Insulin Therapy With or Without Oral Agents: A Randomized, Open-Label, Parallel Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare the effectiveness of Human Regular U-500 Insulin
      three times a day versus twice a day.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 24 in Glycated Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with investigator, baseline total daily dose (TDD; ≤300 or &gt;300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline HbA1c as a covariate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving HbA1c of ≤6.5%, &lt;7.0%, &lt;7.5%, and &lt;8.0% at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The percentage of participants achieving an HbA1c of ≤6.5%, &lt;7.0%, &lt;7.5%, and &lt;8.0% at Week 24 was calculated by the dividing the number of participants meeting the criteria by the total number of participants analyzed, multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-Day Adjusted Rate of Hypoglycemic Events</measure>
    <time_frame>Baseline through Week 24</time_frame>
    <description>Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person [accompanied by neurologic/cognitive impairment]), documented symptomatic (an event which is associated with signs/symptoms of hypoglycemia and plasma glucose [PG] ≤70 milligrams per deciliter [mg/dL]), documented symptomatic nocturnal (any documented symptomatic HE that occurred between bedtime and waking), or asymptomatic (any measured PG ≤70 mg/dL not accompanied by hypoglycemic signs/symptoms). The 30-day adjusted rate of HE is summarized cumulatively at 24 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Body Weight</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or &gt;8%), baseline TDD (≤300 or &gt;300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline body weight as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Total Daily Dose (TDD; Units) of Insulin</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Baseline TDD was defined as the last U-100 insulin TDD prior to receiving the first dose of U-500R insulin. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or &gt;8%), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline TDD as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Total Daily Dose (TDD; Units/kg) of Insulin</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Baseline TDD was defined as the last U-100 insulin TDD prior to receiving the first dose of U-500R insulin. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or &gt;8%), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline TDD as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG) Levels</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or &gt;8%), baseline TDD (≤300 or &gt;300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline FPG as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach HbA1c Target Values</measure>
    <time_frame>Baseline through 6, 12, 18, and 24 weeks.</time_frame>
    <description>The cumulative number of participants achieving an HbA1c of ≤6.5%, &lt;7.0%, &lt;7.5%, and &lt;8.0% is summarized at Weeks 6, 12, 18, and 24. The number of participants at risk (n) is also provided for each target value and timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hypoglycemic Events</measure>
    <time_frame>Baseline through Week 24</time_frame>
    <description>Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person [accompanied by neurologic/cognitive impairment]), documented symptomatic (an event which is associated with signs/symptoms of hypoglycemia and plasma glucose [PG] ≤70 milligrams per deciliter [mg/dL]), documented symptomatic nocturnal (any documented symptomatic HE that occurred between bedtime and waking), or asymptomatic (any measured PG ≤70 mg/dL not accompanied by hypoglycemic signs/symptoms). The percentage of participants with HE at 24 weeks was calculated by the dividing the number of participants meeting the criteria by the total number of participants analyzed, multiplied by 100. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Number of Insulin Injections</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The number of insulin injections per day at baseline (Week 0) and at Week 24 are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 24 in 7-Point Self-Monitored Blood Glucose (SMBG)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The 7-point SMBG is a participant self-administered blood glucose test which utilizes measurements at specific time points over a 24-hour period, including pre-morning meal (fasting), 2 hours after morning meal, pre-midday meal, 2 hours after midday meal, pre-evening meal, 2 hours after evening meal, and 3 AM. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or &gt;8%), baseline TDD (≤300 or &gt;300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline SMBG as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in HbA1c Based on Baseline TDD Insulin ≤2.0 Units/kg and &gt;2.0 Units/kg</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or &gt;2.0 units/kg). LS means of change from baseline were calculated using MMRM with investigator, baseline TDD (≤300 or &gt;300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline HbA1c as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in 30-Day Adjusted Rate of Hypoglycemic Events Based on Baseline TDD Insulin ≤2.0 Units/kg and &gt;2.0 Units/kg</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or &gt;2.0 units/kg). Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person [accompanied by neurologic/cognitive impairment]), documented symptomatic (DS; an event which is associated with signs/symptoms of hypoglycemia and plasma glucose [PG] ≤70 milligrams per deciliter [mg/dL]), or nocturnal (Noc; any documented symptomatic HE that occurred between bedtime and waking). The 30-day adjusted rate of HE is summarized cumulatively at 24 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Percentage of Participants With Hypoglycemic Events Based on Baseline TDD Insulin ≥2.0 Units/kg and &lt;2.0 Units/kg</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Participants were stratified by their baseline TDD insulin (≤2.0 units (U)/kg or &gt;2.0 U/kg). The percentage of participants at risk of developing hypoglycemia (including documented symptomatic, asymptomatic, probable symptomatic, unspecified, or severe hypoglycemia) is presented at Baseline and at Week 24 and was calculated using MMRM fit with options of the binomial distribution and log link function including treatment, TDD (&gt;300 units or ≤300 units), pioglitazone use (yes or no), visit, and treatment-by-visit interaction as fixed effects, and baseline HbA1c value as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Body Weight Based on Baseline TDD Insulin ≥2.0 Units/kg and &lt;2.0 Units/kg</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or &gt;2.0 units/kg). LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or &gt;8%), baseline TDD (≤300 or &gt;300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline body weight as a covariate.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">325</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Human Regular U-500 Insulin TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human Regular U-500 Insulin (U-500R) titrated based on blood glucose readings, administered subcutaneously (SC), three times a day (TID) for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Human Regular U-500 Insulin BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>U-500R Insulin titrated based on blood glucose readings, administered SC, two times a day (BID) for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Regular U-500 Insulin</intervention_name>
    <arm_group_label>Human Regular U-500 Insulin TID</arm_group_label>
    <arm_group_label>Human Regular U-500 Insulin BID</arm_group_label>
    <other_name>LY041001</other_name>
    <other_name>Humulin R</other_name>
    <other_name>U-500R</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          -  Have type 2 diabetes mellitus (World Health Organization [WHO] Classification of
             Diabetes)

          -  Have a body mass index (BMI) ≥25 kilogram per square meter (kg/m^2)

          -  Have Glycated Hemoglobin A1c (HbA1c) ≥7.5% and ≤12.0%, as measured by the central
             laboratory at entry

          -  Current U-100 insulin/analogue users on &gt;200 and ≤600 units per day for ≥3 months at
             study entry and reconfirmed at randomization

          -  Have a history of stable body weight for at least 3 months prior to study entry

          -  Concomitant medications may include metformin (MET), dipeptidyl peptidase-4 (DPP-4)
             inhibitors approved for use with insulin at time of study entry (for example,
             sitagliptin, saxagliptin, and linagliptin), pioglitazone, and/or sulfonylureas
             (SUs)/glinides (repaglinide or nateglinide). Participant's oral antihyperglycemic drug
             (OAD) dose(s) must have been stable for ≥3 months

        Major Exclusion Criteria:

          -  Have type 1 diabetes mellitus or other types of diabetes mellitus apart from type 2
             diabetes mellitus

          -  Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis,
             or alanine aminotransferase or aspartate aminotransferase levels ≥3 times the upper
             limit of the reference range

          -  Have chronic kidney disease stage 4 and higher or history of renal transplantation

          -  Have history of more than 1 episode of severe hypoglycemia within the 6 months prior
             to study entry

          -  Have received insulin by continuous subcutaneous insulin infusion in the 3 months
             prior to study entry

          -  Have received U-500R in the 3 months prior to study entry

          -  Have had a blood transfusion or severe blood loss within 3 months prior to study entry
             or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia

          -  Are taking chronic systemic glucocorticoid therapy or have received such therapy
             within the 4 weeks immediately prior to study entry

          -  Have an irregular sleep/wake cycle

          -  Have used rosiglitazone, once- or twice-daily glucagon-like peptide-1 (GLP-1) receptor
             agents, pramlintide, or other injectable or oral antihyperglycemic therapy not listed
             in the inclusion criteria in the 3 months prior to study entry. Participants may not
             have used once-weekly GLP-1 receptor agents in the 4 months prior to study entry

          -  Have used any weight loss drugs in the 3 months prior to study entry

          -  Have a history of bariatric surgery

          -  Have a history of malignancy other than basal cell or squamous cell skin cancer

          -  Have New York Heart Association (NYHA) Class III or IV per NYHA Cardiac Disease
             Functional Classification

          -  Are breastfeeding or pregnant, or intend to become pregnant during the course of the
             study, or are sexually active women of childbearing potential not actively practicing
             birth control by a method determined by the investigator to be medically acceptable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33619</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Crystal Lake</city>
        <state>Illinois</state>
        <zip>60012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nashua</city>
        <state>New Hampshire</state>
        <zip>03063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <zip>98003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bayamon</city>
        <zip>00956</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Las Lomas</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Manati</city>
        <zip>00674</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <zip>00917-3104</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2013</study_first_submitted>
  <study_first_submitted_qc>January 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2013</study_first_posted>
  <results_first_submitted>April 24, 2015</results_first_submitted>
  <results_first_submitted_qc>April 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 12, 2015</results_first_posted>
  <last_update_submitted>September 3, 2015</last_update_submitted>
  <last_update_submitted_qc>September 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Human Regular U-500 Insulin TID</title>
          <description>Human Regular U-500 Insulin (U-500R) titrated based on blood glucose readings, administered subcutaneously (SC), three times a day (TID) for 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Human Regular U-500 Insulin BID</title>
          <description>U-500R Insulin titrated based on blood glucose readings, administered SC, two times a day (BID) for 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Human Regular U-500 Insulin TID</title>
          <description>U-500R Insulin titrated based on blood glucose readings, administered SC, TID for 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Human Regular U-500 Insulin BID</title>
          <description>U-500R Insulin titrated based on blood glucose readings, administered SC, BID for 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="162"/>
            <count group_id="B2" value="163"/>
            <count group_id="B3" value="325"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.31" spread="10.51"/>
                    <measurement group_id="B2" value="55.50" spread="9.03"/>
                    <measurement group_id="B3" value="55.41" spread="9.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 24 in Glycated Hemoglobin A1c (HbA1c)</title>
        <description>Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with investigator, baseline total daily dose (TDD; ≤300 or &gt;300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline HbA1c as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Randomized participants who received at least 1 dose of U-500R with evaluable HbA1c data.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Regular U-500 Insulin TID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, TID for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Human Regular U-500 Insulin BID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, BID for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Glycated Hemoglobin A1c (HbA1c)</title>
          <description>Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with investigator, baseline total daily dose (TDD; ≤300 or &gt;300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline HbA1c as a covariate.</description>
          <population>Randomized participants who received at least 1 dose of U-500R with evaluable HbA1c data.</population>
          <units>percentage of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.12" spread="0.08"/>
                    <measurement group_id="O2" value="-1.22" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Approximately 325 participants were to be randomized (in a 1:1 ratio of U-500R insulin TID:BID) and 260 were to complete the study (with a 20% dropout rate). The 260 completers would provide a 66.4% chance to show equivalence of TID and BID algorithms, 14.4% chance to show noninferiority of TID, 2.5% chance to superiority of TID, 14.4% chance to show noninferiority of BID, and 2.5% chance to show superiority of BID, assuming a difference in HbA1c change of 0% and a standard deviation of 1.1%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority margin of 0.4% was used.</non_inferiority_desc>
            <p_value>0.3709</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving HbA1c of ≤6.5%, &lt;7.0%, &lt;7.5%, and &lt;8.0% at Week 24</title>
        <description>The percentage of participants achieving an HbA1c of ≤6.5%, &lt;7.0%, &lt;7.5%, and &lt;8.0% at Week 24 was calculated by the dividing the number of participants meeting the criteria by the total number of participants analyzed, multiplied by 100.</description>
        <time_frame>Week 24</time_frame>
        <population>Randomized participants who received at least 1 dose of U-500R, who were not at the HbA1c target at baseline, and had evaluable HbA1c data.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Regular U-500 Insulin TID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, TID for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Human Regular U-500 Insulin BID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, BID for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving HbA1c of ≤6.5%, &lt;7.0%, &lt;7.5%, and &lt;8.0% at Week 24</title>
          <description>The percentage of participants achieving an HbA1c of ≤6.5%, &lt;7.0%, &lt;7.5%, and &lt;8.0% at Week 24 was calculated by the dividing the number of participants meeting the criteria by the total number of participants analyzed, multiplied by 100.</description>
          <population>Randomized participants who received at least 1 dose of U-500R, who were not at the HbA1c target at baseline, and had evaluable HbA1c data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HbA1c ≤6.5% (n=159, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.13"/>
                    <measurement group_id="O2" value="23.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt;7.0% (n=158, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.41"/>
                    <measurement group_id="O2" value="41.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt;7.5% (n=148, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.19"/>
                    <measurement group_id="O2" value="61.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt;8.0% (n=120, 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.50"/>
                    <measurement group_id="O2" value="77.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30-Day Adjusted Rate of Hypoglycemic Events</title>
        <description>Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person [accompanied by neurologic/cognitive impairment]), documented symptomatic (an event which is associated with signs/symptoms of hypoglycemia and plasma glucose [PG] ≤70 milligrams per deciliter [mg/dL]), documented symptomatic nocturnal (any documented symptomatic HE that occurred between bedtime and waking), or asymptomatic (any measured PG ≤70 mg/dL not accompanied by hypoglycemic signs/symptoms). The 30-day adjusted rate of HE is summarized cumulatively at 24 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through Week 24</time_frame>
        <population>Randomized participants who received at least 1 dose of U-500R.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Regular U-500 Insulin TID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, TID for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Human Regular U-500 Insulin BID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, BID for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>30-Day Adjusted Rate of Hypoglycemic Events</title>
          <description>Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person [accompanied by neurologic/cognitive impairment]), documented symptomatic (an event which is associated with signs/symptoms of hypoglycemia and plasma glucose [PG] ≤70 milligrams per deciliter [mg/dL]), documented symptomatic nocturnal (any documented symptomatic HE that occurred between bedtime and waking), or asymptomatic (any measured PG ≤70 mg/dL not accompanied by hypoglycemic signs/symptoms). The 30-day adjusted rate of HE is summarized cumulatively at 24 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
          <population>Randomized participants who received at least 1 dose of U-500R.</population>
          <units>events per participant per 30 days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severe HE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.028"/>
                    <measurement group_id="O2" value="0.009" spread="0.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented Symptomatic HE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.343" spread="3.174"/>
                    <measurement group_id="O2" value="3.885" spread="3.448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented Symptomatic Nocturnal HE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.013" spread="1.438"/>
                    <measurement group_id="O2" value="1.299" spread="1.540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asymptomatic HE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.340" spread="3.215"/>
                    <measurement group_id="O2" value="1.028" spread="2.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Body Weight</title>
        <description>LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or &gt;8%), baseline TDD (≤300 or &gt;300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline body weight as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Randomized participants who received at least 1 dose of U-500R with evaluable body weight data.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Regular U-500 Insulin TID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, TID for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Human Regular U-500 Insulin BID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, BID for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Body Weight</title>
          <description>LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or &gt;8%), baseline TDD (≤300 or &gt;300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline body weight as a covariate.</description>
          <population>Randomized participants who received at least 1 dose of U-500R with evaluable body weight data.</population>
          <units>kilograms (kg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.44" spread="0.41"/>
                    <measurement group_id="O2" value="4.88" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Total Daily Dose (TDD; Units) of Insulin</title>
        <description>Baseline TDD was defined as the last U-100 insulin TDD prior to receiving the first dose of U-500R insulin. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or &gt;8%), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline TDD as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Randomized participants who received at least 1 dose of U-500R with evaluable TDD data.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Regular U-500 Insulin TID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, TID for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Human Regular U-500 Insulin BID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, BID for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Total Daily Dose (TDD; Units) of Insulin</title>
          <description>Baseline TDD was defined as the last U-100 insulin TDD prior to receiving the first dose of U-500R insulin. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or &gt;8%), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline TDD as a covariate.</description>
          <population>Randomized participants who received at least 1 dose of U-500R with evaluable TDD data.</population>
          <units>units</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.19" spread="10.16"/>
                    <measurement group_id="O2" value="51.39" spread="10.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Total Daily Dose (TDD; Units/kg) of Insulin</title>
        <description>Baseline TDD was defined as the last U-100 insulin TDD prior to receiving the first dose of U-500R insulin. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or &gt;8%), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline TDD as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Randomized participants who received at least 1 dose of U-500R with evaluable TDD data.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Regular U-500 Insulin TID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, TID for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Human Regular U-500 Insulin BID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, BID for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Total Daily Dose (TDD; Units/kg) of Insulin</title>
          <description>Baseline TDD was defined as the last U-100 insulin TDD prior to receiving the first dose of U-500R insulin. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or &gt;8%), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline TDD as a covariate.</description>
          <population>Randomized participants who received at least 1 dose of U-500R with evaluable TDD data.</population>
          <units>units per kilogram (units/kg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.08"/>
                    <measurement group_id="O2" value="0.32" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG) Levels</title>
        <description>LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or &gt;8%), baseline TDD (≤300 or &gt;300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline FPG as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Randomized participants who received at least 1 dose of U-500R with evaluable FPG data.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Regular U-500 Insulin TID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, TID for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Human Regular U-500 Insulin BID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, BID for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG) Levels</title>
          <description>LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or &gt;8%), baseline TDD (≤300 or &gt;300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline FPG as a covariate.</description>
          <population>Randomized participants who received at least 1 dose of U-500R with evaluable FPG data.</population>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.66" spread="5.64"/>
                    <measurement group_id="O2" value="-8.86" spread="5.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach HbA1c Target Values</title>
        <description>The cumulative number of participants achieving an HbA1c of ≤6.5%, &lt;7.0%, &lt;7.5%, and &lt;8.0% is summarized at Weeks 6, 12, 18, and 24. The number of participants at risk (n) is also provided for each target value and timepoint.</description>
        <time_frame>Baseline through 6, 12, 18, and 24 weeks.</time_frame>
        <population>Randomized participants who received at least 1 dose of U-500R, who were not at the HbA1c target at baseline, and had evaluable HbA1c data</population>
        <group_list>
          <group group_id="O1">
            <title>Human Regular U-500 Insulin TID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, TID for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Human Regular U-500 Insulin BID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, BID for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach HbA1c Target Values</title>
          <description>The cumulative number of participants achieving an HbA1c of ≤6.5%, &lt;7.0%, &lt;7.5%, and &lt;8.0% is summarized at Weeks 6, 12, 18, and 24. The number of participants at risk (n) is also provided for each target value and timepoint.</description>
          <population>Randomized participants who received at least 1 dose of U-500R, who were not at the HbA1c target at baseline, and had evaluable HbA1c data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HbA1c ≤6.5%, Week 6 (n=154, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c ≤6.5%, Week 12 (n=145, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c ≤6.5%, Week 18 (n=140, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c ≤6.5%, Week 24 (n=76, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt;7.0%, Week 6 (n=154, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt;7.0%, Week 12 (n=148, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt;7.0%, Week 18 (n=144, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt;7.0%, Week 24 (n=53, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt;7.5%, Week 6 (n=144, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt;7.5%, Week 12 (n=140, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt;7.5%, Week 18 (n=136, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt;7.5%, Week 24 (n=34, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt;8.0%, Week 6 (n=117, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt;8.0%, Week 12 (n=114, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt;8.0%, Week 18 (n=111, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt;8.0%, Week 24 (n=20, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Hypoglycemic Events</title>
        <description>Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person [accompanied by neurologic/cognitive impairment]), documented symptomatic (an event which is associated with signs/symptoms of hypoglycemia and plasma glucose [PG] ≤70 milligrams per deciliter [mg/dL]), documented symptomatic nocturnal (any documented symptomatic HE that occurred between bedtime and waking), or asymptomatic (any measured PG ≤70 mg/dL not accompanied by hypoglycemic signs/symptoms). The percentage of participants with HE at 24 weeks was calculated by the dividing the number of participants meeting the criteria by the total number of participants analyzed, multiplied by 100. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through Week 24</time_frame>
        <population>Randomized participants who received at least 1 dose of U-500R.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Regular U-500 Insulin TID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, TID for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Human Regular U-500 Insulin BID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, BID for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hypoglycemic Events</title>
          <description>Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person [accompanied by neurologic/cognitive impairment]), documented symptomatic (an event which is associated with signs/symptoms of hypoglycemia and plasma glucose [PG] ≤70 milligrams per deciliter [mg/dL]), documented symptomatic nocturnal (any documented symptomatic HE that occurred between bedtime and waking), or asymptomatic (any measured PG ≤70 mg/dL not accompanied by hypoglycemic signs/symptoms). The percentage of participants with HE at 24 weeks was calculated by the dividing the number of participants meeting the criteria by the total number of participants analyzed, multiplied by 100. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
          <population>Randomized participants who received at least 1 dose of U-500R.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severe HE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85"/>
                    <measurement group_id="O2" value="3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented Symptomatic HE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.98"/>
                    <measurement group_id="O2" value="90.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented Symptomatic Nocturnal HE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.78"/>
                    <measurement group_id="O2" value="80.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asymptomatic HE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.20"/>
                    <measurement group_id="O2" value="66.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Number of Insulin Injections</title>
        <description>The number of insulin injections per day at baseline (Week 0) and at Week 24 are presented.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Randomized participants who received at least 1 dose of U-500R. Last observation carried forward (LOCF) was used to impute missing postbaseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Regular U-500 Insulin TID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, TID for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Human Regular U-500 Insulin BID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, BID for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Number of Insulin Injections</title>
          <description>The number of insulin injections per day at baseline (Week 0) and at Week 24 are presented.</description>
          <population>Randomized participants who received at least 1 dose of U-500R. Last observation carried forward (LOCF) was used to impute missing postbaseline values.</population>
          <units>injections per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.765" spread="1.234"/>
                    <measurement group_id="O2" value="4.783" spread="1.307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.000" spread="0.000"/>
                    <measurement group_id="O2" value="2.000" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 24 in 7-Point Self-Monitored Blood Glucose (SMBG)</title>
        <description>The 7-point SMBG is a participant self-administered blood glucose test which utilizes measurements at specific time points over a 24-hour period, including pre-morning meal (fasting), 2 hours after morning meal, pre-midday meal, 2 hours after midday meal, pre-evening meal, 2 hours after evening meal, and 3 AM. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or &gt;8%), baseline TDD (≤300 or &gt;300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline SMBG as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Randomized participants who received at least 1 dose of U-500R with evaluable SMBG data.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Regular U-500 Insulin TID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, TID for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Human Regular U-500 Insulin BID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, BID for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 24 in 7-Point Self-Monitored Blood Glucose (SMBG)</title>
          <description>The 7-point SMBG is a participant self-administered blood glucose test which utilizes measurements at specific time points over a 24-hour period, including pre-morning meal (fasting), 2 hours after morning meal, pre-midday meal, 2 hours after midday meal, pre-evening meal, 2 hours after evening meal, and 3 AM. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or &gt;8%), baseline TDD (≤300 or &gt;300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline SMBG as a covariate.</description>
          <population>Randomized participants who received at least 1 dose of U-500R with evaluable SMBG data.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-morning Meal (n=150, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.10" spread="3.96"/>
                    <measurement group_id="O2" value="-29.19" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Hours After Morning Meal (n=146, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.68" spread="4.29"/>
                    <measurement group_id="O2" value="-31.32" spread="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-midday Meal (n=150, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.54" spread="4.17"/>
                    <measurement group_id="O2" value="-32.26" spread="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Hours After Midday Meal (n=143, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.31" spread="4.50"/>
                    <measurement group_id="O2" value="-22.53" spread="4.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-evening Meal (n=150, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.17" spread="3.93"/>
                    <measurement group_id="O2" value="-32.96" spread="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Hours After Evening Meal (n=147, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.56" spread="4.13"/>
                    <measurement group_id="O2" value="-38.36" spread="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 AM (n=147, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.77" spread="4.34"/>
                    <measurement group_id="O2" value="-47.82" spread="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in HbA1c Based on Baseline TDD Insulin ≤2.0 Units/kg and &gt;2.0 Units/kg</title>
        <description>Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or &gt;2.0 units/kg). LS means of change from baseline were calculated using MMRM with investigator, baseline TDD (≤300 or &gt;300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline HbA1c as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Randomized participants who received at least 1 dose of U-500R with evaluable HbA1c data.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Regular U-500 Insulin TID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, TID for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Human Regular U-500 Insulin BID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, BID for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in HbA1c Based on Baseline TDD Insulin ≤2.0 Units/kg and &gt;2.0 Units/kg</title>
          <description>Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or &gt;2.0 units/kg). LS means of change from baseline were calculated using MMRM with investigator, baseline TDD (≤300 or &gt;300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline HbA1c as a covariate.</description>
          <population>Randomized participants who received at least 1 dose of U-500R with evaluable HbA1c data.</population>
          <units>percentage of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline TDD ≤2.0 units/kg (n=50, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.99" spread="0.14"/>
                    <measurement group_id="O2" value="-1.32" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline TDD &gt;2.0 units/kg (n=112, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="0.10"/>
                    <measurement group_id="O2" value="-1.18" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in 30-Day Adjusted Rate of Hypoglycemic Events Based on Baseline TDD Insulin ≤2.0 Units/kg and &gt;2.0 Units/kg</title>
        <description>Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or &gt;2.0 units/kg). Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person [accompanied by neurologic/cognitive impairment]), documented symptomatic (DS; an event which is associated with signs/symptoms of hypoglycemia and plasma glucose [PG] ≤70 milligrams per deciliter [mg/dL]), or nocturnal (Noc; any documented symptomatic HE that occurred between bedtime and waking). The 30-day adjusted rate of HE is summarized cumulatively at 24 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Randomized participants who received at least 1 dose of U-500R.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Regular U-500 Insulin TID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, TID for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Human Regular U-500 Insulin BID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, BID for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in 30-Day Adjusted Rate of Hypoglycemic Events Based on Baseline TDD Insulin ≤2.0 Units/kg and &gt;2.0 Units/kg</title>
          <description>Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or &gt;2.0 units/kg). Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person [accompanied by neurologic/cognitive impairment]), documented symptomatic (DS; an event which is associated with signs/symptoms of hypoglycemia and plasma glucose [PG] ≤70 milligrams per deciliter [mg/dL]), or nocturnal (Noc; any documented symptomatic HE that occurred between bedtime and waking). The 30-day adjusted rate of HE is summarized cumulatively at 24 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
          <population>Randomized participants who received at least 1 dose of U-500R.</population>
          <units>events per participant per 30 days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severe HE, TDD ≤2 units/kg, Baseline (n=50, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe HE, TDD ≤2 units/kg, Week 24 (n=50, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.025"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe HE, TDD &gt;2 units/kg, Baseline (n=112, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe HE, TDD &gt;2 units/kg, Week 24 (n=112, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.029"/>
                    <measurement group_id="O2" value="0.013" spread="0.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DS HE, TDD ≤2 units/kg, Baseline (n=50, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.958" spread="4.808"/>
                    <measurement group_id="O2" value="1.454" spread="3.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DS HE, TDD ≤2 units/kg, Week 24 (n=50, 46))</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.356" spread="2.352"/>
                    <measurement group_id="O2" value="3.131" spread="3.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DS HE, TDD &gt;2 units/kg, Baseline (n=112, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.037" spread="4.382"/>
                    <measurement group_id="O2" value="1.730" spread="3.180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DS HE, TDD &gt;2 units/kg, Week 24 (n=112, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.784" spread="3.397"/>
                    <measurement group_id="O2" value="4.186" spread="3.509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Noc. HE, TDD ≤2 units/kg, Baseline (n=50, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.066" spread="2.045"/>
                    <measurement group_id="O2" value="0.711" spread="1.965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Noc. HE, TDD ≤2 units/kg, Week 24 (n=50, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.105" spread="1.153"/>
                    <measurement group_id="O2" value="1.282" spread="1.431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Noc. HE, TDD &gt;2 units/kg, Baseline (n=112, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.792" spread="2.465"/>
                    <measurement group_id="O2" value="0.585" spread="1.445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Noc. HE, TDD &gt;2 units/kg, Week 24 (n=112, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.522" spread="2.018"/>
                    <measurement group_id="O2" value="1.753" spread="1.934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Percentage of Participants With Hypoglycemic Events Based on Baseline TDD Insulin ≥2.0 Units/kg and &lt;2.0 Units/kg</title>
        <description>Participants were stratified by their baseline TDD insulin (≤2.0 units (U)/kg or &gt;2.0 U/kg). The percentage of participants at risk of developing hypoglycemia (including documented symptomatic, asymptomatic, probable symptomatic, unspecified, or severe hypoglycemia) is presented at Baseline and at Week 24 and was calculated using MMRM fit with options of the binomial distribution and log link function including treatment, TDD (&gt;300 units or ≤300 units), pioglitazone use (yes or no), visit, and treatment-by-visit interaction as fixed effects, and baseline HbA1c value as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Randomized participants who received at least 1 dose of U-500R.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Regular U-500 Insulin TID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, TID for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Human Regular U-500 Insulin BID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, BID for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Percentage of Participants With Hypoglycemic Events Based on Baseline TDD Insulin ≥2.0 Units/kg and &lt;2.0 Units/kg</title>
          <description>Participants were stratified by their baseline TDD insulin (≤2.0 units (U)/kg or &gt;2.0 U/kg). The percentage of participants at risk of developing hypoglycemia (including documented symptomatic, asymptomatic, probable symptomatic, unspecified, or severe hypoglycemia) is presented at Baseline and at Week 24 and was calculated using MMRM fit with options of the binomial distribution and log link function including treatment, TDD (&gt;300 units or ≤300 units), pioglitazone use (yes or no), visit, and treatment-by-visit interaction as fixed effects, and baseline HbA1c value as a covariate.</description>
          <population>Randomized participants who received at least 1 dose of U-500R.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline TDD≤2.0 U/kg, Baseline risk (n=50, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.00"/>
                    <measurement group_id="O2" value="39.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline TDD ≤2.0 U/kg, Week 24 risk (n=50, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.00"/>
                    <measurement group_id="O2" value="86.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline TDD &gt;2.0 U/kg, Baseline risk (n=112, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.32"/>
                    <measurement group_id="O2" value="51.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline TDD &gt;2.0 U/kg, Week 24 risk (n=112, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.43"/>
                    <measurement group_id="O2" value="97.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Body Weight Based on Baseline TDD Insulin ≥2.0 Units/kg and &lt;2.0 Units/kg</title>
        <description>Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or &gt;2.0 units/kg). LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or &gt;8%), baseline TDD (≤300 or &gt;300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline body weight as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Randomized participants who received at least 1 dose of U-500R with evaluable body weight data.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Regular U-500 Insulin TID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, TID for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Human Regular U-500 Insulin BID</title>
            <description>U-500R Insulin titrated based on blood glucose readings, administered SC, BID for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Body Weight Based on Baseline TDD Insulin ≥2.0 Units/kg and &lt;2.0 Units/kg</title>
          <description>Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or &gt;2.0 units/kg). LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or &gt;8%), baseline TDD (≤300 or &gt;300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline body weight as a covariate.</description>
          <population>Randomized participants who received at least 1 dose of U-500R with evaluable body weight data.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline TDD insulin ≤2.0 units/kg (n=50, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.11" spread="0.88"/>
                    <measurement group_id="O2" value="6.09" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline TDD insulin &gt;2.0 units/kg (n=112, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.08" spread="0.44"/>
                    <measurement group_id="O2" value="4.40" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The Serious Adverse Events and Other Adverse Events Tables include all randomized participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Human Regular U-500 Insulin TID</title>
          <description>U-500R Insulin titrated based on blood glucose readings, administered SC, TID for 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Human Regular U-500 Insulin BID</title>
          <description>U-500R Insulin titrated based on blood glucose readings, administered SC, BID for 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Endometrial cancer stage i</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Viith nerve paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="162"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="162"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="162"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="162"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="162"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

